Secukinumab 300 mg for active ankylosing spondylitis in Chinese adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 4, randomized, double-blind, placebo-controlled trial enrolled Chinese adults with active ankylosing spondylitis who were naïve to biologic DMARDs and had an inadequate response to at least two NSAIDs. Participants were randomized 1:1 to secukinumab 300 mg subcutaneously or placebo for a 16-week double-blind period. Those who completed Period 1 entered an open-label extension and received secukinumab 300 mg for an additional 36 weeks, yielding 52 weeks total follow-up. Baseline requirements included BASDAI ≥4 and patient-reported total back pain ≥4, and certain conventional synthetic DMARDs were permitted if doses were stable.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant with a clinical diagnosis of ankylosing spondylitis (AS) and meeting the modified New York criteria for AS.
* Participant must have baseline disease activity as defined by having a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score \>= 4 and a Patient's Assessment of ●Total Back Pain score \>= 4 based on a 0 - 10 numeric rating scale (NRS) at the Screening and Baseline visits.
* Participant has had an inadequate response to at least two nonsteroidal anti-inflammatory drugs (NSAIDs) over an at least 4-week period in total at maximum recommended or tolerated doses, or participant has an intolerance to or contraindication for NSAIDs as defined by the Investigator.
* If entering the study on concomitant methotrexate (MTX), leflunomide, sulfasalazine (SSZ), and/or hydroxychloroquine, participant must be on a stable dose of MTX (\<= 25 mg/week) and/or SSZ (\<= 3 g/day) and/or hydroxychloroquine (\<= 400 mg/day) or leflunomide (\<= 20 mg/day) for at least 28 days prior to the Baseline visit. A combination of up to two background conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) is allowed except the combination of MTX and leflunomide.
* If entering the study on concomitant oral corticosteroids, participant must be on a stable dose of prednisone (\<= 10 mg/day), or oral corticosteroid equivalents, for at least 14 days prior to the Baseline visit.
* If entering the study on concomitant NSAIDs, tramadol, combination of acetaminophen and codeine or hydrocodone, and/or non-opioid analgesics, participant must be on stable dose(s) for at least 14 days prior to the Baseline visit.

Exclusion Criteria:

* Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib).
* Prior exposure to any biologic therapy with a potential therapeutic impact on spondyloarthritis (SpA).
* Intra-articular joint injections, spinal/paraspinal injection(s), or parenteral administration of corticosteroids within 28 days prior to the Baseline visit. Inhaled or topical corticosteroids are allowed.
* Participant on any other DMARDs (other than those allowed), thalidomide or apremilast within 28 days or five half-lives (whichever is longer) of the drug prior to the Baseline visit.
* Participant on opioid analgesics (except for combination acetaminophen/codeine or acetaminophen/hydrocodone which are allowed) or use of inhaled marijuana within 14 days prior to the Baseline visit.
* Participant has a history of inflammatory arthritis of different etiology other than axial SpA (including but not limited to rheumatoid arthritis, psoriatic arthritis, mixed connective tissue disease, systemic lupus erythematosus, reactive arthritis, scleroderma, polymyositis, dermatomyositis, fibromyalgia), or any arthritis with onset prior to 17 years of age.
* Laboratory values meeting the following criteria within the Screening period prior to the first dose of study drug: serum aspartate transaminase \> 2 × upper limit of normal (ULN); serum alanine transaminase \> 2 × ULN; estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal Disease formula \< 40 milliliter (mL)/minute/1.73m\^2; hemoglobin \< 10 gram/deciliter, total white blood cell count \< 2,500/microliter (μL); absolute neutrophil count \< 1,500/μL; absolute lymphocyte count \< 800/μL; and platelet count \< 100,000/μL.

Where it's running

• Department of RheumatologyTongji Hospital
  Wuhan, Hubei, China Recruiting
• Tongji Hospital
  Wuhan, Hubei, China Recruiting
• Tongji Hospital
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: Yu Yikai, M.d
• Email: yuyikai@163.com
• Phone: 15671678920

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MST-931 in healthy adults

  This early-phase study tests a single subcutaneous dose of MST-931 to see if it is safe and how it behaves in the body in healthy adults.

  Recruiting Phase 1 Mabsoft Therapeutics (Shanghai) Co., Ltd. · Herston, Queensland · NCT07903493

• Secukinumab retention in adults with plaque psoriasis and MASLD in Spain

  This study tests how long people with plaque psoriasis and MASLD stay on secukinumab in real-world Spain, using EMR data from several hospitals.

  Recruiting at 9 sites Novartis · Badalona, Barcelona and 8 other locations · NCT07683065

• ESPB for persistent back pain in ankylosing spondylitis

  This trial tests whether an erector spinae plane block can help reduce persistent back pain in adults with ankylosing spondylitis who still have pain despite controlled disease activity.

  Recruiting Marmara University · Istanbul, Pendik · NCT07633730

• Effect of smartphone use on neck posture and function in RA/AS patients and healthy controls

  This study tests how smartphone use relates to neck posture, tongue pressure, balance, and neck-related disability in people with rheumatoid arthritis or ankylosing spondylitis compared with healthy individuals.

  Recruiting Necmettin Erbakan University · Konya, Meram · NCT07627542

• Combining Traditional Chinese and Western medicine to improve function in ankylosing spondylitis

  We will test whether combining Traditional Chinese and Western medicine improves how well adults with ankylosing spondylitis can function after six months.

  Recruiting China-Japan Friendship Hospital · Beijing, Beijing Municipality · NCT07556224

• Long-term real-world tracking of secukinumab treatment for moderate to severe hidradenitis suppurativa in Italy

  This project will see how secukinumab works and is used in adults with moderate to severe hidradenitis suppurativa in Italy.

  Recruiting at 16 sites Novartis · Ancona, AN and 15 other locations · NCT07543419

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.